Literature DB >> 15965670

Clinical value of dacryoscintigraphy using a simplified analysis.

P L Jager1, K Mansour, H Vrakkink-de Zoete, L Poot, J M M Hooijmans, K J Bruin, L J Blanksma.   

Abstract

PURPOSE: To study the discriminatory ability of dacryoscintigraphy in differentiating between patients with epiphora and volunteers using a simple method.
METHODS: Twenty eyes in ten volunteers and 66 eyes in 55 patients with severe epiphora were studied. Dacryoscintigraphy (15 frames of 1 min) was performed after administration of 4 MBq (99m)Tc-pertechnetate (10 mul) in both eyes. By mapping a single region of interest (ROI) over the conjunctival sac we determined T1 (%dose in first minute) and linear clearance rate (LCR, defined as [see text] from the tracer disappearance curve. Reproducibility was determined in volunteers. Conjunctival resorption was determined from completely obstructed systems. Sensitivity and specificity were calculated and receiver operating characteristics (ROC) analysis was conducted.
RESULTS: In volunteers mean T1 was 52.8+/-11.9% (95% CI 47.1-58.4%), and LCR was 74.2+/-11.1% (95% CI 69.0-79.4%). Reproducibility was good (mean difference 4.1+/-13.3% for T1 and 0.7+/-17% for LCR). Epiphora patients had clearly higher T1 (82.1+/-15.2%, P<0.0001) and lower LCR (38.9+/-22.5%, P<0.0001) values. Tracer resorption was 24%. Based on ROC analysis 70% for T1 and 50% for LCR were considered optimal cut-off levels to separate patients from volunteers. Sensitivity/specificity were 77/95% for T1 and 71/100% for LCR. T1 and LCR values did not correlate with symptom scores or Anel test results.
CONCLUSION: Dacryoscintigraphy, using LCR and T1 as parameters, is a reliable and objective method to detect tear-flow abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965670     DOI: 10.1007/s00417-004-1038-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  18 in total

1.  Quantitative lacrimal scintillography. I. Method and physiological application.

Authors:  J J Hurwitz; M N Maisey; R A Welham
Journal:  Br J Ophthalmol       Date:  1975-06       Impact factor: 4.638

2.  Dacryocystorhinostomy for epiphora in the presence of a patent lacrimal system.

Authors:  B O'Donnell; R Shah
Journal:  Clin Exp Ophthalmol       Date:  2001-02       Impact factor: 4.207

3.  Scintigraphy and contrast radiography for epiphora.

Authors:  J D Rose; C B Clayton
Journal:  Br J Radiol       Date:  1985-12       Impact factor: 3.039

4.  Methodological aspects of tear flow determination by means of a radioactive tracer.

Authors:  T Sorensen; F T Jensen
Journal:  Acta Ophthalmol (Copenh)       Date:  1977-10

5.  Lacrimal scintigraphy. I. Compartmental analysis of data.

Authors:  T E Hilditch; C S Kwok; L A Amanat
Journal:  Br J Ophthalmol       Date:  1983-11       Impact factor: 4.638

6.  Lacrimal scintigraphy. III. Physiological aspects of lacrimal drainage.

Authors:  L A Amanat; T E Hilditch; C S Kwok
Journal:  Br J Ophthalmol       Date:  1983-11       Impact factor: 4.638

7.  Lacrimal dacryoscintigraphy.

Authors:  H von Denffer; J Dressler; H W Pabst
Journal:  Semin Nucl Med       Date:  1984-01       Impact factor: 4.446

8.  Quantitative lacrimal scintillography.

Authors:  R M Chavis; R A Welham; M N Maisey
Journal:  Arch Ophthalmol       Date:  1978-11

9.  Lacrimal scintigraphy. II. Its role in the diagnosis of epiphora.

Authors:  L A Amanat; T E Hilditch; C S Kwok
Journal:  Br J Ophthalmol       Date:  1983-11       Impact factor: 4.638

10.  The role of dacryocystography in the management of patients with epiphora.

Authors:  J Nixon; I W Birchall; J Virjee
Journal:  Br J Radiol       Date:  1990-05       Impact factor: 3.039

View more
  1 in total

1.  The value of lacrimal scintillography in the assessment of patients with epiphora.

Authors:  O A Vonica; E Obi; Z Sipkova; C Soare; A R Pearson
Journal:  Eye (Lond)       Date:  2017-03-03       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.